Compare BridgeBio Pharma Inc (BBIO) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Nike Inc — how do they compare? BridgeBio Pharma Inc trades at $82.56 (market cap $16.46B), while Nike Inc trades at $42.88 (market cap $63.47B). The key difference: Nike Inc is far larger — about 3.9× BridgeBio Pharma Inc's market cap, and Nike Inc pays a 3.83% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NKE | |
|---|---|---|
Market Cap | $16.46B | $63.47B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $79.24 |
52-Week Low | $44.81 | $40.75 |
Enterprise Value | $18.02B | $65.48B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nike (NKE) trades at $43.76, down 1.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $46.31B for 2025 with a net income margin of 6.7%, though earnings have beaten expectations in recent quarters. Analysts maintain a consensus buy rating with a $50.80 price target, suggesting potential upside from current levels.
Nike's outlook is supported by strong brand equity and consistent earnings beats, but faces headwinds from softer demand in China and margin pressure. The stock presents a value opportunity with a P/E of 20.41 below historical averages, though execution risks in the turnaround strategy remain key for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
